Comparative Pharmacology
Head-to-head clinical analysis: CLARINEX versus X TROZINE L A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARINEX versus X TROZINE L A.
CLARINEX vs X-TROZINE L.A.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desloratadine is a long-acting tricyclic histamine antagonist with selective peripheral H1-receptor antagonist activity. It inhibits histamine release from mast cells and reduces allergic inflammation.
X-TROZINE L.A. is a piperazine derivative that acts as a centrally acting alpha-2 adrenergic agonist, reducing sympathetic outflow from the brainstem, leading to decreased peripheral vascular resistance and lowered blood pressure.
5 mg orally once daily.
250 mg orally once daily. May be increased to 500 mg once daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 27 hours (range 20-30 hours). This long half-life supports once-daily dosing and allows for steady-state concentrations within 7 days.
12-15 hours; prolonged in renal impairment (up to 30 hours in CrCl <30 mL/min).
Desloratadine is primarily eliminated via renal excretion (~40% as metabolites) and fecal elimination (~45% as metabolites). Less than 2% is excreted unchanged in urine.
Primarily renal (70-80% as unchanged drug), with 20-30% fecal via biliary excretion.
Category C
Category C
Antihistamine
Antihistamine